Single center, DBRPCT of tofacitinib 11 mg/d vs PBO in 100 knee OA pts (KL Gr 1-2); At wk 12 there was NO significant differences betw groups in VAS Pain, or other outcomes-WOMAC, Oxford Knee Score, EQ-5D-5L, analgesic use https://t.co/VDtgY7hTm4 https://t.co/PveouQbI8r
Links:
Efficacy and Safety of Tofacitinib Versus Placebo in Patients With Early‐Grade …
https://buff.ly/fOLyxDV
Sep-22-2026


